Our studies revealed a mechanism for ColXVIII in the regulation of ErbB signaling in BC that leads to tumor promotion and demonstrated marked upregulation of ColXVIII in high-grade BCs that was associated with a poor clinical outcome. The gene discussed is EGFR; the disease is breast cancer.